News | RIVM

Safety of materials and products already starts at the design phase

The Ministry of Infrastructure and Water Management aims to ensure that all new materials and technological developments are safe in 2050.

Onderzoeker met veiligheidsbril bekijkt preparaat

Vaccination coverage increases for second consecutive year, by 10% for HPV

The percentage of children receiving vaccinations from the National Immunisation Programme rose again last year. Another striking note is the 10% increase in HPV vaccination, rising to 63%.

Het aantal jonge vrouwen dat zich laat vaccineren tegen HPV is toegenomen met 10%

Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years

National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.

A pregnant woman can protect her baby against whooping cough with 22-week vaccination

From 16 December 2019, pregnant women in the Netherlands will be offered the 22-week vaccination. With this vaccination, a pregnant woman protects her child and herself against whooping cough.

Health effects due to titanium nanoparticles in food and toothpaste cannot be excluded

Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.

Step forward in the battle against pertussis

Addition of an extra adjuvant (additive) to the current pertussis vaccines could enhance the effectivity of these vaccines.

Tool for risk assessment of nanomaterials in cosmetics

Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.

Nanotechnology increasingly used in medical devices

The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.

Cost-effective risk assessment of nanomaterials may be feasible

Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.

Innovation required in risk assessment of nanoparticles

The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.